Zentalis Pharmaceuticals, Inc. - 10-Q Filing
Zentalis Pharmaceuticals filed its Q1 2026 10-Q report with the SEC on May 8, 2026. The filing includes unaudited financial statements for the quarter ended March 31, 2026, and provides details about research and development expenses, general and administrative costs, stock-based compensation activity, and contingent liabilities related to its Zentera Therapeutics collaboration. No material revenue or earnings figures were disclosed in this excerpt.
Tickers: $ZNTL